kestra medical technologies ltd - KMTS

KMTS

Close Chg Chg %
19.49 0.13 0.67%

Pre-Market

19.62

+0.13 (0.67%)

Volume: 395.00K

Last Updated:

Apr 8, 2026, 4:00 PM EDT

Company Overview: kestra medical technologies ltd - KMTS

KMTS Key Data

Open

$20.50

Day Range

19.25 - 20.90

52 Week Range

13.25 - 30.00

Market Cap

$1.15B

Shares Outstanding

58.37M

Public Float

19.22M

Beta

1.09

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.81

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

533.21K

 

KMTS Performance

1 Week
 
-1.11%
 
1 Month
 
2.83%
 
3 Months
 
-19.69%
 
1 Year
 
-19.19%
 
5 Years
 
N/A
 

KMTS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About kestra medical technologies ltd - KMTS

Kestra Medical Technologies Ltd. is a commercial-stage, wearable medical device and digital healthcare company. It focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Traci S. Umberger in 2014 and is headquartered in Kirkland, WA.

KMTS At a Glance

Kestra Medical Technologies Ltd.
3933 Lake Washington Boulevard NE
Kirkland, Washington 98033
Phone 1-425-279-8002 Revenue 59.82M
Industry Medical Specialties Net Income -113,814,000.00
Sector Health Technology 2025 Sales Growth 115.054%
Fiscal Year-end 04 / 2026 Employees 330
View SEC Filings

KMTS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 20.655
Price to Book Ratio 6.015
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -10.59
Enterprise Value to Sales 17.423
Total Debt to Enterprise Value 0.043

KMTS Efficiency

Revenue/Employee 181,257.576
Income Per Employee -344,890.909
Receivables Turnover 7.402
Total Asset Turnover 0.345

KMTS Liquidity

Current Ratio 6.723
Quick Ratio 6.55
Cash Ratio 6.256

KMTS Profitability

Gross Margin 40.475
Operating Margin -177.845
Pretax Margin -190.051
Net Margin -190.277
Return on Assets -65.733
Return on Equity -131.471
Return on Total Capital -45.577
Return on Invested Capital -86.738

KMTS Capital Structure

Total Debt to Total Equity 21.572
Total Debt to Total Capital 17.744
Total Debt to Total Assets 14.983
Long-Term Debt to Equity 21.481
Long-Term Debt to Total Capital 17.67
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kestra Medical Technologies Ltd - KMTS

Collapse All in section
All values USD millions. 2023 2024 2025 5-year trend
Sales/Revenue
- 7.63M 27.81M 59.81M
Sales Growth
- - +264.53% +115.05%
-
Cost of Goods Sold (COGS) incl D&A
- 18.28M 27.45M 35.60M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 4.86M 11.56M 7.97M
Depreciation
- 4.86M 11.56M 7.97M
Amortization of Intangibles
- - - -
-
COGS Growth
- - +50.17% +29.70%
-
Gross Income
- (10.65M) 362.00K 24.21M
Gross Income Growth
- - +103.40% +6,587.85%
-
Gross Profit Margin
- -139.59% +1.30% +40.47%
2023 2024 2025 5-year trend
SG&A Expense
- 69.77M 85.42M 130.59M
Research & Development
- 15.76M 15.49M 15.65M
Other SG&A
- 54.01M 69.94M 114.94M
SGA Growth
- - +22.44% +52.87%
-
Other Operating Expense
- - - -
-
Unusual Expense
- - - (2.65M)
-
EBIT after Unusual Expense
- (80.42M) (85.06M) (103.73M)
Non Operating Income/Expense
- 1.83M (2.80M) (2.21M)
Non-Operating Interest Income
- - - 3.20M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 5.63M 6.23M 7.73M
Interest Expense Growth
- - +10.68% +24.14%
-
Gross Interest Expense
- 5.63M 6.23M 7.73M
Interest Capitalized
- - - -
-
Pretax Income
- (84.22M) (94.10M) (113.68M)
Pretax Income Growth
- - -11.72% -20.81%
-
Pretax Margin
- -1,103.84% -338.30% -190.05%
Income Tax
- 15.00K 24.00K 135.00K
Income Tax - Current - Domestic
- 15.00K 24.00K 135.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
- (84.24M) (94.12M) (113.81M)
Minority Interest Expense
- - - -
-
Net Income
- (84.24M) (94.12M) (113.81M)
Net Income Growth
- - -11.73% -20.92%
-
Net Margin Growth
- -1,104.04% -338.39% -190.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
- (84.24M) (94.12M) (113.81M)
Preferred Dividends
- 2.50M 6.72M 12.32M
Net Income Available to Common
- (86.74M) (100.84M) (126.14M)
EPS (Basic)
- -1.7511 -2.0358 -2.4564
EPS (Basic) Growth
- - -16.26% -20.66%
-
Basic Shares Outstanding
- 49.53M 49.53M 51.35M
EPS (Diluted)
- -1.7511 -2.0358 -2.4564
EPS (Diluted) Growth
- - -16.26% -20.66%
-
Diluted Shares Outstanding
- 49.53M 49.53M 51.35M
EBITDA
- (75.57M) (73.50M) (98.41M)
EBITDA Growth
- - +2.73% -33.89%
-
EBITDA Margin
- -990.38% -264.27% -164.52%

Snapshot

Average Recommendation BUY Average Target Price 28.714
Number of Ratings 7 Current Quarters Estimate -0.59
FY Report Date 04 / 2026 Current Year's Estimate -2.343
Last Quarter’s Earnings -0.61 Median PE on CY Estimate N/A
Year Ago Earnings -5.13 Next Fiscal Year Estimate -2.195
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate -0.59 -0.54 -2.34 -2.20
High Estimates -0.55 -0.46 -2.30 -1.91
Low Estimate -0.61 -0.59 -2.37 -2.37
Coefficient of Variance -3.86 -8.44 -1.06 -7.04

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Kestra Medical Technologies Ltd - KMTS

Date Name Shares Transaction Value
Feb 20, 2026 Brian Webster See Remarks; Director 383,151 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.39 per share 9,728,203.89
Feb 20, 2026 Brian Webster See Remarks; Director 379,879 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.29 per share 9,987,018.91
Feb 20, 2026 Brian Webster See Remarks; Director 379,786 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.18 per share 10,322,583.48

Kestra Medical Technologies Ltd in the News